Withdrawn application: Gazyvaro, obinutuzumab, Date of withdrawal: 04/07/2023, Post-authorisation
Human medicines European public assessment report (EPAR): Fosavance, alendronic acid,colecalciferol, Osteoporosis, Postmenopausal, Date of authorisation: 24/08/2005, Revision: 27, Status: Authorised
ACT EU multi-stakeholder platform kick-off workshop, European Medicines Agency and online, day 1: 13:00 - 18:30, day 2: 08:30 - 13:30, Amsterdam time (CEST), from 22/06/2023 to 23/06/2023
Opinion/decision on a Paediatric investigation plan (PIP): Batoclimab, decision type: , therapeutic area: , PIP number: P/0452/2022
Opinion/decision on a Paediatric investigation plan (PIP): Fusion protein composed of the first 2 immunoglobulin (Ig)-like domains of the human ROBO2 fused to human IgG1 Fc (PF-06730512), decision type: , therapeutic area: , PIP number: P/0431/2022
Tauroselcholic [75Se] acid : List of nationally authorised medicinal products - PSUSA/00010486/202301
Opinion/decision on a Paediatric investigation plan (PIP): Efavaleukin alfa, decision type: , therapeutic area: , PIP number: P/0432/2022
Human medicines European public assessment report (EPAR): Cholib, fenofibrate,simvastatin, Dyslipidemias, Date of authorisation: 26/08/2013, Revision: 16, Status: Authorised
Focus group on veterinary pharmacovigilance reporting in poultry, European Medicines Agency, from 11/10/2023 to 11/10/2023
Opinion/decision on a Paediatric investigation plan (PIP): Odronextamab, decision type: , therapeutic area: , PIP number: P/0426/2022